成都先导收盘上涨2.31%，滚动市盈率105.26倍，总市值69.16亿元

Group 1 - The core viewpoint of the articles highlights Chengdu Xian Dao's strong market position in the medical service industry, with a high PE ratio compared to industry averages [1][2] - As of March 31, 2025, Chengdu Xian Dao had 16,254 shareholders, an increase of 2,538 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in drug development services related to DEL technology, offering services such as DEL screening, custom DEL libraries, FBDD/SBDD, custom drug development, and chemical synthesis [1] Group 2 - In the first quarter of 2025, the company reported revenue of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.28 million yuan, a year-on-year increase of 102.90%, with a gross margin of 51.87% [2] - Chengdu Xian Dao's rolling PE ratio is 105.26, significantly higher than the industry average of 41.42 and the median of 44.32, ranking 40th in the medical service sector [2] - The company has obtained 138 invention patents and 13 software copyrights, with over 300 additional invention patents currently under application [1]